Genomics of Drug Sensitivity in Cancer |
Motesanib
|
Synonyms |
AMG-706, AMG 706, AMG706
|
Targets |
VEGFR, RET, KIT, PDGFR
|
Target pathway |
RTK signaling
|
PubCHEM ID |
11667893
|
Jsmol |
|
Download molecule |
11667893
|
PUBCHEM IUPAC INCHI |
InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
|
Smiles |
O=C(NC2(=CC=1(NCC(C=1C=C2)(C)C)))C3(=C(N=CC=C3)NCC4(=CC=NC=C4))
|
Cluster number |
63
|
calculated LogS |
-4,512
|
Molecular weight |
373,459
|
calculated LogP |
2,3483
|
H-Acceptors |
6
|
H-Donors |
3
|
Ro5 violations |
0
|
Druglikeness |
0,599
|
DrugScore |
0,586415257548615
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Fish Toxicity |
Low FHMT
|
Fish Toxicity2 |
1,6124
|
Rat Acute Toxicity |
2,799
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2-
|
Caco-2 Permeability2 |
0,6372
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor2 |
Inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,5147
|
AMES Toxicity |
Non AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP450 2C19 Inhibitor |
Inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-3,4918
|